Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Context Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Context Therapeutics Inc.’s stock price such as:

• Context Therapeutics Inc.’s current stock price and volume
• Why Context Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for CNTX from analysts
• CNTX’s stock price momentum as measured by its relative strength

About Context Therapeutics Inc. (CNTX)

Before we jump into Context Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Want to learn more about Context Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Context Therapeutics Inc..

Context Therapeutics Inc.’s Stock Price as of Market Close

As of April 28, 2026, 4:00 PM, CST, Context Therapeutics Inc.’s stock price was $2.510.

Context Therapeutics Inc. is up 7.26% from its previous closing price of $2.340.

During the last market session, Context Therapeutics Inc.’s stock traded between $2.320 and $2.540. Currently, there are approximately 95.18 million shares outstanding for Context Therapeutics Inc..

Context Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Context Therapeutics Inc. Stock Price History

Context Therapeutics Inc.’s (CNTX) price is currently down 4.2% so far this month.

During the month of April, Context Therapeutics Inc.’s stock price has reached a high of $2.960 and a low of $2.170.

Over the last year, Context Therapeutics Inc. has hit prices as high as $3.620 and as low as $0.490. Year to date, Context Therapeutics Inc.’s stock is up 70.75%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Context Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 28, 2026, there were 2 analysts who downgraded Context Therapeutics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Context Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Context Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Context Therapeutics Inc. (CNTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Context Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 28, 2026, Context Therapeutics Inc. has a weighted four-quarter relative price strength of 22.13%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Context Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Context Therapeutics Inc. Stock Price: Bottom Line

As of April 28, 2026, Context Therapeutics Inc.’s stock price is $2.510, which is up 7.26% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Context Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.